Ozempic-Maker Novo Open to Upgrading US Listing for Direct Investor Access
Macro·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novo Nordisk's CEO Mike Doustdar expressed openness to enhancing the company's US listing. He noted that there are 'advantages' in providing US investors with direct access to the Danish group's stock.
This potential move reflects the company's strategy to engage more effectively with American investors amid growing interest in its products, particularly Ozempic.
Novo Nordisk
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Boss Mike Doustdar says he sees ‘advantages’ in giving US investors direct access to Danish group’s stock”
FT — Ozempic-maker Novo open to upgrading US listing